On April 8, 2024 Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, reported preclinical data from MYTX-011, its investigational cMET-targeting ADC, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Mythic Therapeutics, APR 8, 2024, View Source;utm_medium=rss&utm_campaign=mythic-therapeutics-presents-preclinical-data-on-mytx-011-an-investigational-cmet-targeting-antibody-drug-conjugate-adc-at-the-american-association-for-cancer-research-aacr-annual-meeting [SID1234641874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Patients with tumors expressing low-to-moderate levels of cMET have not been able to fully benefit from ADC therapies available today, and we continue to be encouraged by the progress made with MYTX-011," said Brian Fiske, Ph.D., Chief Scientific Officer and Co-founder of Mythic. "We previously demonstrated that MYTX-011 drives increased internalization and cytotoxicity in tumor cells expressing moderate cMET levels compared to a matched parent ADC in vitro. This new study adds to our excitement by illustrating how our FateControl technology, incorporated into MYTX-011, enables increased delivery of the ADC’s cytotoxic payload to tumors with moderate cMET expression in vivo. We’re also pleased to present data that highlight the potential of MYTX-011 as a therapeutic candidate for treating multiple types of solid tumors that express cMET."

MYTX-011 is an investigational, pH-sensitive, vcMMAE-based ADC that is designed to benefit not only patients whose tumors express high levels of cMET, but also a broader set of patients whose tumors express low to moderate levels of cMET. MYTX-011 is engineered to rapidly dissociate from cMET only at the acidic pH of endolysosomes.

In studies presented at AACR (Free AACR Whitepaper), the pH-engineered antibody component of MYTX-011 demonstrated markedly increased accumulation in cancer cells expressing high, moderate or low cMET levels compared to its matched non-engineered parent antibody. Consistent with this finding, MYTX-011 demonstrated broader and more potent cMET-dependent cytotoxicity across a panel of cancer cell lines compared to a matched parent ADC. Moreover, in mice bearing NSCLC xenograft tumors with moderate cMET expression, MYTX-011 treatment delivered increased levels of MMAE payload to tumors in vivo as compared to the parent ADC. MYTX-011 was shown to be highly active in cMET+ xenograft models derived from gastric, esophageal and head and neck cancers. Together, these findings provide preclinical proof-of-concept of the potential of MYTX-011 as a therapeutic candidate for treating a broader range of cMET-expressing malignancies.

About MYTX-011

MYTX-011, an investigational cMET-targeting ADC, leverages Mythic’s innovative FateControl technology, which allows antibody-drug conjugates (ADCs) to actively navigate inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells. This breakthrough approach takes the next step beyond linker-payload technologies and is designed to improve ADC efficacy against a broad set of molecular targets and patient profiles. MYTX-011 is currently being evaluated in the Phase 1 KisMET-01 clinical trial, a first-in-human, open-label, multi-center, dose escalation and dose expansion study enrolling patients with locally advanced, recurrent or metastatic NSCLC (NCT05652868).